Japanese investors think Prime Minister Shinzo Abe's "third arrow" economic liberalization plan, along with his party's control of both houses of legislature, could mean help is on the way for the country's tiny biotech venture space.

Change will not happen overnight given how deeply the challenges run, but the proposals could be adopted as soon as this fall and could have an impact starting next year.